<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03024580</url>
  </required_header>
  <id_info>
    <org_study_id>64/16</org_study_id>
    <nct_id>NCT03024580</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer</brief_title>
  <acronym>MEGA</acronym>
  <official_title>A Pilot Study Evaluating Megestrol Acetate Modulation in Advanced Breast Cancer With Positive Hormonal Receptor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK Cambridge Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors
      in advanced breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progesterone receptor (PR) expression has been considered a biomarker of oestrogen receptor-α
      (ERα) activity. This longstanding relationship has been recently challenged and instead of
      being merely an ERα-induced gene target, PR may be a critical determinant of ERα activity.
      The functional significance of this steroid receptor crosstalk is regulation of a gene
      expression program associated with low tumorigenicity; hence, better disease outcome. Genomic
      alterations in the PR genomic locus seem to be a relatively common mechanism for reduction of
      PR expression, which may consequently lead to altered ERα chromatin binding and target gene
      expression patterns that increase breast tumorigenicity and confers a poor clinical outcome.
      This ERα-PR crosstalk may be directly influenced by many variables, including the relative
      receptor levels and the hormonal milieu.

      ER-positive advanced breast cancer is a heterogeneous group of diseases with considerable
      variability in outcome to a range of treatments. Prior response predicts the likelihood of
      subsequent benefit from another endocrine agent and this should be taken into account in the
      treatment decision process when assessing whether to prescribe a subsequent endocrine
      therapy. Despite the enormous progress made regarding the elucidation of breast cancer
      subgroups and their molecular drivers, most information comes from primary tumors. MA lacks
      cross-resistance and is active after acquired resistance to potent AI. This pilot trial
      evaluates in vivo MA modulation of steroidal receptors in advanced breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until disease progression or death due to any cause, assessed up to 18 months</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until death, assessed up to 18 months</time_frame>
    <description>From date of randomization until the date of death from any cause, assessed up to 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit</measure>
    <time_frame>Partial response and stable disease for more than 24 weeks, assessed up to 18 months</time_frame>
    <description>Partial response and stable disease for more than 24 weeks, as per RECIST criteria, from date of randomization until the date of first documented progression or date of death, whichever came first, assessed up to 18 months</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Megestrol acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol Acetate 160Mg Tablet</intervention_name>
    <description>Megestrol acetate 160 mg PO daily</description>
    <arm_group_label>Megestrol acetate</arm_group_label>
    <other_name>MA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole 1Mg Tablet</intervention_name>
    <description>Anastrozole 1 mg PO daily OR</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>Anastrozole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5Mg Tablet</intervention_name>
    <description>Letrozole 2.5 mg PO daily OR</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Letrozole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane 25 MG</intervention_name>
    <description>Exemestane 25 mg PO daily</description>
    <arm_group_label>Exemestane</arm_group_label>
    <other_name>Exemestane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen 20Mg Tablet</intervention_name>
    <description>Tamoxifen 20 mg PO daily</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Tamoxifen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant 50Mg Solution for Injection</intervention_name>
    <description>Fulvestrant 500 mg IM d1, d14, d28 and q28 days</description>
    <arm_group_label>Fulvestrant</arm_group_label>
    <other_name>Fulvestrant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic breast cancer with ER and/or PR positive (primary tumor)

          -  Metastatic site amenable to biopsy

        Exclusion Criteria:

          -  Platelet count below 100,000 / mm3

          -  Renal or hepatic impairment

          -  Coagulation disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Bines, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Cancer, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Carroll, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research UK Cambridge Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renata Obadia, RN</last_name>
    <phone>552132073810</phone>
    <email>robadia@inca.gov.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital do Cancer III</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Obadia, RN</last_name>
      <phone>552132073810</phone>
      <email>robadia@inca.gov.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Megestrol Acetate</keyword>
  <keyword>Steroid, Receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

